<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02409368</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-171</org_study_id>
    <secondary_id>2014-001285-10</secondary_id>
    <nct_id>NCT02409368</nct_id>
  </id_info>
  <brief_title>An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC</brief_title>
  <acronym>Checkmate 171</acronym>
  <official_title>An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the occurrence of high-grade (CTCAE v4.0 Grades&#xD;
      3-4), treatment-related, select adverse events in patients with advanced or metastatic&#xD;
      Squamous Cell Non-Small Cell Lung Cancer (SqNSCLC) with progression of disease during or&#xD;
      after at least 1 systemic therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 29, 2015</start_date>
  <completion_date type="Actual">August 27, 2021</completion_date>
  <primary_completion_date type="Actual">March 7, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events</measure>
    <time_frame>From first dose to time of analysis of primary endpoint (approximately up to 34 months)</time_frame>
    <description>The total number of participants with high grade treatment related select adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With High Grade Select Adverse Events</measure>
    <time_frame>From first dose to time of analysis of primary endpoint (approximately up to 34 months)</time_frame>
    <description>The total number of participants with high grade select adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Onset of Any Grade Select Adverse Events</measure>
    <time_frame>From first dose to time of analysis of primary endpoint (approximately up to 34 months)</time_frame>
    <description>Median Time to onset of any grade select adverse events reported up to 30 days after last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Time to Resolution of Any Grade Select Adverse Events</measure>
    <time_frame>From first dose to time of analysis of primary endpoint (approximately up to 34 months)</time_frame>
    <description>Median time to resolution of any grade select adverse events reported up to 30 days after last dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From first dose to time of analysis of primary endpoint (approximately up to 34 months)</time_frame>
    <description>OS is defined as the time from first dosing date to the date of death. A subject who has not died will be censored at last known date alive. OS will be followed continuously while subjects are on treatment and every 3 months via in-person or phone contact after subjects discontinue the study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>From first dose to time of analysis of primary endpoint (approximately up to 34 months)</time_frame>
    <description>ORR is defined as the percentage of subjects with a best overall response (BOR) of confirmed CR or PR with respect to all treated participants. ORR as assessed by the investigator will be reported.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">810</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A: Treatment - Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Cohort A: Treatment - Nivolumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit&#xD;
        www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG Status: PS 0-1 &amp; PS 2&#xD;
&#xD;
          -  Subjects with histologically or cytologically-documented SqNSCLC&#xD;
&#xD;
          -  Subjects must have experienced disease progression or recurrence during or after one&#xD;
             prior platinum doublet-based chemotherapy regimen&#xD;
&#xD;
          -  Subjects must have evaluable disease by CT or MRI per RECIST 1.1 criteria&#xD;
&#xD;
          -  Subjects with treated or asymptomatic CNS metastases&#xD;
&#xD;
          -  Prior palliative radiotherapy must have been completed at least 14 days prior to study&#xD;
             drug administration&#xD;
&#xD;
          -  Prior lines of antineoplastic therapy, including hemotherapy, hormonal therapy,&#xD;
             immunotherapy, surgical resection of lesions, non-palliative radiation therapy, or&#xD;
             standard or investigational agents for treatment of NSCLC, must be completed 28 days&#xD;
             prior to the first dose of nivolumab&#xD;
&#xD;
          -  Males and Females, ages 18 or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with untreated, symptomatic CNS metastases&#xD;
&#xD;
          -  Subjects with carcinomatous meningitis&#xD;
&#xD;
          -  Subjects with active, known or suspected autoimmune disease.&#xD;
&#xD;
          -  Subjects who received prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2,&#xD;
             anti-CD137, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or&#xD;
             drug specifically targeting T-cell costimulation or checkpoint pathways) or who have&#xD;
             previously taken part in a randomized BMS clinical trial for nivolumab or ipilimumab.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wels</city>
        <zip>4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Odense C</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pori</city>
        <zip>FI-28500</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Athens</city>
        <zip>145 64</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Patras</city>
        <zip>26504</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pécs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dublin 8</city>
        <state>Dublin</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Galway</city>
        <zip>ST4 6QG</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gdansk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gliwice</city>
        <zip>44-101</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Medyczny Santa Familia Sp. z o.o.</name>
      <address>
        <city>Lodz</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Poznan</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zabrze</city>
        <zip>41-803</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-602</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lisboa</city>
        <zip>1099-023</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lisboa</city>
        <zip>1769-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bucharest</city>
        <zip>030171</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cluj Napoca</city>
        <zip>400015</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400058</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oradea</city>
        <zip>410469</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Timisoara</city>
        <zip>300167</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>8916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>La Laguna</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Goteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Middlesex Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>N18 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maidstone Hospital</name>
      <address>
        <city>Maidstone</city>
        <state>Kent</state>
        <zip>ME16 9QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bebington</city>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cottingham</city>
        <zip>HU16 5JQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 OYN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <zip>W1T 7HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Northwood</city>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 5SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospitals NHS Trust</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 1, 2015</study_first_submitted>
  <study_first_submitted_qc>April 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2015</study_first_posted>
  <results_first_submitted>March 31, 2021</results_first_submitted>
  <results_first_submitted_qc>July 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 29, 2021</results_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02409368/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 29, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/68/NCT02409368/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>810 participants enrolled and treated</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ECOG (PS0)</title>
          <description>ECOG Performance Status 0&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>ECOG (PS1)</title>
          <description>ECOG Performance Status 1&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
        </group>
        <group group_id="P3">
          <title>ECOG (PS 2)</title>
          <description>ECOG Performance Status 2&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="173"/>
                <participants group_id="P2" count="534"/>
                <participants group_id="P3" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="489"/>
                <participants group_id="P3" count="99"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse event unrelated to study drug</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="101"/>
                <participants group_id="P2" count="346"/>
                <participants group_id="P3" count="63"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>maximum clinical benefit</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>poor/non compliant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>study drug toxicity</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>no longer meets study criteria</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant request to discontinue</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Reported</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ECOG (PS0)</title>
          <description>ECOG Performance Status 0&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>ECOG (PS1)</title>
          <description>ECOG Performance Status 1&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>ECOG (PS 2)</title>
          <description>ECOG Performance Status 2&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="173"/>
            <count group_id="B2" value="534"/>
            <count group_id="B3" value="103"/>
            <count group_id="B4" value="810"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="8.31"/>
                    <measurement group_id="B2" value="66.1" spread="8.28"/>
                    <measurement group_id="B3" value="67.8" spread="7.25"/>
                    <measurement group_id="B4" value="65.8" spread="8.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="170"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="423"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="497"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="749"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="527"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="796"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events</title>
        <description>The total number of participants with high grade treatment related select adverse events.</description>
        <time_frame>From first dose to time of analysis of primary endpoint (approximately up to 34 months)</time_frame>
        <population>All Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>ECOG (PS0)</title>
            <description>ECOG Performance Status 0&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>ECOG (PS1)</title>
            <description>ECOG Performance Status 1&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>ECOG (PS 2)</title>
            <description>ECOG Performance Status 2&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With High Grade (Grade 3, 4 and 5) Treatment Related Select Adverse Events</title>
          <description>The total number of participants with high grade treatment related select adverse events.</description>
          <population>All Treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="534"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypersensitivity/ Infusion reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With High Grade Select Adverse Events</title>
        <description>The total number of participants with high grade select adverse events.</description>
        <time_frame>From first dose to time of analysis of primary endpoint (approximately up to 34 months)</time_frame>
        <population>All Treated participants</population>
        <group_list>
          <group group_id="O1">
            <title>ECOG (PS0)</title>
            <description>ECOG Performance Status 0&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>ECOG (PS1)</title>
            <description>ECOG Performance Status 1&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>ECOG (PS 2)</title>
            <description>ECOG Performance Status 2&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With High Grade Select Adverse Events</title>
          <description>The total number of participants with high grade select adverse events.</description>
          <population>All Treated participants</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="534"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypersensitivity/ Infusion reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Onset of Any Grade Select Adverse Events</title>
        <description>Median Time to onset of any grade select adverse events reported up to 30 days after last dose</description>
        <time_frame>From first dose to time of analysis of primary endpoint (approximately up to 34 months)</time_frame>
        <population>All Treated Participants</population>
        <group_list>
          <group group_id="O1">
            <title>ECOG (PS0)</title>
            <description>ECOG Performance Status 0&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>ECOG (PS1)</title>
            <description>ECOG Performance Status 1&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>ECOG (PS 2)</title>
            <description>ECOG Performance Status 2&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Onset of Any Grade Select Adverse Events</title>
          <description>Median Time to onset of any grade select adverse events reported up to 30 days after last dose</description>
          <population>All Treated Participants</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="534"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Endrocrine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.00" lower_limit="2.3" upper_limit="75.7"/>
                    <measurement group_id="O2" value="10.14" lower_limit="1.9" upper_limit="112.0"/>
                    <measurement group_id="O3" value="13.86" lower_limit="6.1" upper_limit="55.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.71" lower_limit="0.1" upper_limit="88.0"/>
                    <measurement group_id="O2" value="8.50" lower_limit="0.1" upper_limit="88.1"/>
                    <measurement group_id="O3" value="6.00" lower_limit="0.3" upper_limit="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="54"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.14" lower_limit="1.4" upper_limit="85.9"/>
                    <measurement group_id="O2" value="10.43" lower_limit="2.0" upper_limit="77.9"/>
                    <measurement group_id="O3" value="7.21" lower_limit="2.0" upper_limit="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="33"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.93" lower_limit="7.4" upper_limit="68.0"/>
                    <measurement group_id="O2" value="10.57" lower_limit="0.6" upper_limit="94.0"/>
                    <measurement group_id="O3" value="3.93" lower_limit="0.1" upper_limit="26.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="46"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.14" lower_limit="4.1" upper_limit="62.1"/>
                    <measurement group_id="O2" value="17.43" lower_limit="0.7" upper_limit="107.1"/>
                    <measurement group_id="O3" value="10.29" lower_limit="1.4" upper_limit="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="126"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.07" lower_limit="0.1" upper_limit="92.1"/>
                    <measurement group_id="O2" value="7.86" lower_limit="0.1" upper_limit="75.9"/>
                    <measurement group_id="O3" value="12.64" lower_limit="2.1" upper_limit="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypersensitivity/Infusion Reaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" lower_limit="1.7" upper_limit="73.4"/>
                    <measurement group_id="O2" value="2.21" lower_limit="0.3" upper_limit="20.3"/>
                    <measurement group_id="O3" value="2.14" lower_limit="2.1" upper_limit="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Time to Resolution of Any Grade Select Adverse Events</title>
        <description>Median time to resolution of any grade select adverse events reported up to 30 days after last dose</description>
        <time_frame>From first dose to time of analysis of primary endpoint (approximately up to 34 months)</time_frame>
        <population>All Treated Participants</population>
        <group_list>
          <group group_id="O1">
            <title>ECOG (PS0)</title>
            <description>ECOG Performance Status 0&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>ECOG (PS1)</title>
            <description>ECOG Performance Status 1&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>ECOG (PS 2)</title>
            <description>ECOG Performance Status 2&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Median Time to Resolution of Any Grade Select Adverse Events</title>
          <description>Median time to resolution of any grade select adverse events reported up to 30 days after last dose</description>
          <population>All Treated Participants</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="534"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Endrocrine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="58"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="1.7" upper_limit="108.3">insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="1.0" upper_limit="108.3">insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="6.1" upper_limit="88.0">insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" lower_limit="0.1" upper_limit="89.1"/>
                    <measurement group_id="O2" value="3.71" lower_limit="0.1" upper_limit="37.9"/>
                    <measurement group_id="O3" value="1.29" lower_limit="0.1" upper_limit="29.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.43" lower_limit="1.7" upper_limit="9.0"/>
                    <measurement group_id="O2" value="4.86" lower_limit="0.3" upper_limit="92.6"/>
                    <measurement group_id="O3" value="3.57" lower_limit="0.6" upper_limit="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="0.3" upper_limit="105.0"/>
                    <measurement group_id="O2" value="4.00" lower_limit="0.1" upper_limit="61.7"/>
                    <measurement group_id="O3" value="NA" lower_limit="2.3" upper_limit="50.7">insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.14" lower_limit="4.4" upper_limit="25.9"/>
                    <measurement group_id="O2" value="6.000" lower_limit="0.1" upper_limit="107.1"/>
                    <measurement group_id="O3" value="59.1" lower_limit="0.6" upper_limit="59.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.00" lower_limit="2.1" upper_limit="101.4"/>
                    <measurement group_id="O2" value="15.29" lower_limit="0.1" upper_limit="123.1"/>
                    <measurement group_id="O3" value="5.71" lower_limit="1.1" upper_limit="58.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypersensitivity/Infusion Reaction</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" lower_limit="0.1" upper_limit="2.1"/>
                    <measurement group_id="O2" value="0.14" lower_limit="0.1" upper_limit="82.3"/>
                    <measurement group_id="O3" value="0.14" lower_limit="0.1" upper_limit="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>OS is defined as the time from first dosing date to the date of death. A subject who has not died will be censored at last known date alive. OS will be followed continuously while subjects are on treatment and every 3 months via in-person or phone contact after subjects discontinue the study drug.</description>
        <time_frame>From first dose to time of analysis of primary endpoint (approximately up to 34 months)</time_frame>
        <population>All Treated Participants</population>
        <group_list>
          <group group_id="O1">
            <title>ECOG (PS0)</title>
            <description>ECOG Performance Status 0&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>ECOG (PS1)</title>
            <description>ECOG Performance Status 1&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>ECOG (PS 2)</title>
            <description>ECOG Performance Status 2&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>OS is defined as the time from first dosing date to the date of death. A subject who has not died will be censored at last known date alive. OS will be followed continuously while subjects are on treatment and every 3 months via in-person or phone contact after subjects discontinue the study drug.</description>
          <population>All Treated Participants</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="376"/>
                <count group_id="O3" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" lower_limit="9.9" upper_limit="13.4"/>
                    <measurement group_id="O2" value="10.3" lower_limit="9.5" upper_limit="11.3"/>
                    <measurement group_id="O3" value="5.2" lower_limit="3.0" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Response Rate (ORR)</title>
        <description>ORR is defined as the percentage of subjects with a best overall response (BOR) of confirmed CR or PR with respect to all treated participants. ORR as assessed by the investigator will be reported.</description>
        <time_frame>From first dose to time of analysis of primary endpoint (approximately up to 34 months)</time_frame>
        <population>All Response Evaluable Participants</population>
        <group_list>
          <group group_id="O1">
            <title>ECOG (PS0)</title>
            <description>ECOG Performance Status 0&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>ECOG (PS1)</title>
            <description>ECOG Performance Status 1&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>ECOG (PS 2)</title>
            <description>ECOG Performance Status 2&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR)</title>
          <description>ORR is defined as the percentage of subjects with a best overall response (BOR) of confirmed CR or PR with respect to all treated participants. ORR as assessed by the investigator will be reported.</description>
          <population>All Response Evaluable Participants</population>
          <units>Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
                <count group_id="O2" value="455"/>
                <count group_id="O3" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="4.2" upper_limit="13.5"/>
                    <measurement group_id="O2" value="11.6" lower_limit="8.8" upper_limit="15.0"/>
                    <measurement group_id="O3" value="1.6" lower_limit="0.0" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>approximately 39 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ECOG PS 0</title>
          <description>ECOG Performance Status 0&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>ECOG PS 1</title>
          <description>ECOG Performance Status 1&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
        </group>
        <group group_id="E3">
          <title>ECOG PS 2</title>
          <description>ECOG Performance Status 2&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
        </group>
        <group group_id="E4">
          <title>Total</title>
          <description>Total&#xD;
nivolumab 3 mg/kg as a 60- minute IV infusion every 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="376" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="568" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="297" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="71" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="461" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Tracheo-oesophageal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia of malignancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hypophysitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Bacterial diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Clostridium colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Mediastinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Parainfluenzae virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Tracheal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Bone disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Patellofemoral pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Follicular thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="152" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Small intestine adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Tumour compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Bronchopneumopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Oesophagobronchial fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Respiratory tract haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Superior vena cava occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="459" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="687" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="96" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="139" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="100" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="94" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="135" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="100" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="171" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="181" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="62" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="71" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="52" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="180" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="189" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="152" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="218" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="65" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="54" subjects_at_risk="810"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="534"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="810"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <phone>Please Email</phone>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

